Skip to main content

Advertisement

Table 2 Baseline characteristics of the first 115 subjects at inclusion in the OMEMI trial; Data presented as percentages or median values (25, 75 percentiles)

From: Effects of omega 3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study

Age (y) 75 (72, 78)
Gender (male/female) (%) 73.9/26.1
Current smoker (%) 11.3
BMI (kg/m2) 25.5 (23.9, 28.1)
S-total cholesterol (mmol/L) 3.80 (3.20, 4.40)
S-LDL (mmol/L) 2.06 (1.69, 2.52)
S-HDL (mmol/L) 1.26 (1.03, 1.59)
S-triglycerides (mmol/L) 1.15 (0.88, 1.54)
Systolic blood pressure (mmHg) 135 (125, 150)
Pulse rate (bpm) 66 (60, 72)
STEMI (%) 33.9
Troponin-T (peak level) (ng/L) 735 (168, 2562)
Previous atrial fibrillation (%) 13.9
Previous myocardial infarction (n) 46 (40.0%)
Aspirin (%) 93.9
Clopidogrel (%) 40.8
Prasugrel (%) 12.1
Ticagrelor (%) 40.0
Anticoagulation (%) 16.5
Betablocker (%) 89.5
ACE-I/AT II blocker (%) 64.3
Calcium channel blocker (%) 21.7
Statin (%) 96.5
Diuretic (%) 27.8
Nitrates (%) 13.0
n-3 PUFA supplements (%) 47.3
  1. ACE-I/AT II: angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; S-LDL: low density lipoprotein; S-HDL: high-density lipoprotein; STEMI: ST-segment elevation myocardial infarction.